Tandem Diabetes Care (TNDM) FY2017 results: revenue $108 million, up 27.7% on the year
Tandem Diabetes Care Inc. (TNDM) reported revenue of $108 million for fiscal 2017, the year ended 31 December 2017, up 27.7% on the year before. Net income was -$73 million, and diluted earnings per share $-12.87. The figures are the company's own, from the 10-K it filed with the SEC on 26 February 2019.
Revenue
$108 million
+27.7% on the year
FY2012FY2017
Operating margin
-58.5%
-92.6% a year earlier
FY2012FY2017
Net income
-$73 million
FY2012FY2017
Diluted EPS
-$12.87
FY2012FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
108
84.2
72.8
+27.7%
Cost of revenue
63.5
60.7
46.3
+4.7%
Gross profit
44.1
23.6
26.6
+86.9%
Gross margin
41.0%
28.0%
36.5%
Research and development
20.7
18.8
17.0
+9.8%
Selling, general and administrative
86.4
82.8
78.6
+4.3%
Operating income
-62.9
-78.1
-69.0
Operating margin
-58.5%
-92.6%
-94.7%
Pre-tax income
-73.0
-83.5
-72.4
Income tax
0.0
-0.0
0.0
Net income
-73.0
-83.4
-72.4
Net margin
-67.9%
-99.0%
-99.4%
Diluted EPS
-$12.87
-$27.30
-$25.00
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
-66.1
-61.2
-58.8
Capital expenditure
5.7
8.9
5.8
-36.0%
Free cash flow
-71.9
-70.1
-64.5
Free cash flow margin
-66.8%
-83.2%
-88.6%
Cash from investing
2.8
10.4
n/a
-73.4%
Cash from financing
40.4
52.3
n/a
-22.8%
Depreciation and amortisation
6.9
5.5
4.8
+25.1%
Share-based compensation
12.6
11.7
13.1
+8.3%
Shares outstanding at period end
10m
3m
3m
+225.4%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
-29.1
-5.9
63.5
Debt
82.7
81.1
30.2
+2.0%
Other liabilities
41.8
37.2
31.1
+12.1%
Total liabilities and equity
95.3
112
125
-15.2%
Fixed assets
19.6
18.4
15.5
+6.6%
Investments
0.5
8.9
28.0
-94.6%
Cash and equivalents
13.7
44.7
43.1
-69.3%
Receivables
20.8
11.2
14.1
+86.1%
Inventory
27.0
21.2
17.5
+27.4%
Other assets
13.8
8.1
6.5
+70.2%
Total assets
95.3
112
125
-15.2%
10-K for the year ended 31 December 2017, filed 26 February 2019: the filing.